For the second year in a row Novartis has been named the most innovative pharma company in the industry by the Innovation Index, a collaboration between CNS Summit and IDEA Pharma.
“The differentiator between Novartis and the competition was the nature of these innovative initiatives, which showed strong potential to be transformative, rather than incremental,” said a report on the index, which measures companies’ advances in trial optimization, clinical innovation and use of digital technology.
For the first time in 22 years, the International Council on Harmonization (ICH) is almost completely overhauling the guideline ICH E8 — General Considerations for Clinical Studies, the international standard for designing and developing trials. Read More
The following summary of CenterWatch’s 2019 Global Site Relationship Survey presents sites’ views on the CROs they work with. In last month’s issue, we provided details on their sponsor relationship views, as well as data on the types, locations and therapeutic areas of the site responding to the survey (CenterWatch Monthly, November 2019).
Sites are looking for improvements in almost all areas of their working relationships with CROs, but particularly in the areas of contracting and budget, according to a new CenterWatch survey.
We’ve all heard the stories of deliberate data fraud in clinical trials: the investigator who created fictional subjects, the lab technician who duplicated test data, the coordinator who altered records. What makes people think they can get away with it? Read More